Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan-Feb;40(3Part-II):534-543.
doi: 10.12669/pjms.40.3.8397.

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

Yonghua Min  1 , Xiaofeng Li  2 , Huafei Chen  3 , Yumei Xu  4 , Gang Lan  5
Affiliations
Review

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

Yonghua Min et al. Pak J Med Sci. 2024 Jan-Feb.

Abstract

Background & objective: Previous studies have suggested that the modified Glasgow Prognostic Score (mGPS) could be a potential biomarker for lung cancer (LC). However, the association between mGPS and overall survival (OS) or progression-free survival (PFS) in lung cancer patients remains unclear. The purpose of our study was to investigate possible correlation between mGPS and OS or PFS in LC patients.

Methods: An extensive search of PubMed, Cochrane Library, EMbase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Trip Database, Worldwide Science, and Google Scholar databases was done for relevant articles, published prior to May 30, 2021, that report correlation between mGPS and OS or PFS in LC patients. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used as the main parameters for evaluation.

Results: A total of 28 studies involving 9,748 lung cancer patients were analysed. The pooled analysis revealed that elevated mGPS (≥ 0) was associated with poor OS (HR=1.54; 95% CI, 1.32-1.77) and PFS (HR=1.49; 95% CI, 1.17-1.82). Furthermore, a significant correlation between mGPS (1 or 2) and OS was observed. However, no significant correlation was found between mGPS (1 or 2) and PFS. Subgroup analysis based on ethnicity demonstrated that mGPS ≥ 0 was associated with worse OS compared to mGPS=0 in both Asian (HR=1.46; 95% CI, 1.04-1.89; p<0.05) and Caucasian (HR=1.64; 95% CI, 1.35-1.94; p<0.05) cohorts of LC patients.

Conclusions: Our results demonstrate that positive mGPS is associated with poor survival results. Therefore, mGPS may be used as a biomarker for predicting prognosis in LC patients.

Keywords: Lung cancer; Meta-analysis; Prognosis; Systematic review; Systemic inflammation; mGPS.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None.

Figures

Fig.1
Fig.1
Flow diagram for the selection of studies and specific reasons for exclusion from the present meta-analysis.
Fig.2
Fig.2
Forest plot of the association between modified Glasgow prognostic score (mGPS) and overall survival (OS) in patients with lung cancer.
Fig.3
Fig.3
Forest plot of the association between modified Glasgow prognostic score (mGPS) and progression free survival (PFS) in patients with lung cancer.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019, CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551. - PubMed
    1. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011:a population-based study. Lancet Lond Engl. 2015;385(9974):1206–1218. doi:10.1016/S0140-6736(14)61396-9. - PubMed
    1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349. - PubMed
    1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241. doi:10.3322/caac.21149. - PubMed
    1. Aberle DR, Adams AM. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011(365):395–409. doi:10.1056/NEJMoa1102873. - PMC - PubMed

LinkOut - more resources